https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35334 Wed 17 Nov 2021 16:28:12 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25037 Wed 11 Apr 2018 16:51:50 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22836 Wed 11 Apr 2018 16:12:13 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14210 Wed 11 Apr 2018 15:00:30 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:49280 Wed 10 May 2023 13:13:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31406 Wed 08 Jan 2020 11:28:03 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23592 Wed 08 Jan 2020 11:27:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:24894 Wed 06 Apr 2022 14:00:12 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14209 Tue 24 Aug 2021 14:39:08 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42384 2peak) and heart rate (HR_peak) were recorded. There were no differences (p > 0.05) in mean VO_2peak among the three tests (min-max: 17.08–18.09 mL kg⁻¹ min^−1,). For individuals, small discrepancies in VO_2peak between the 6MWT and other tests were greater with higher fitness levels. HRpeak was significantly (p = 0.005) lower during the 6MWT. Correlations between VO_2peak and performance measures within each test were high (6MWT VO_2peak and distance: r = 0.78, SWT VO_2peak and shuttles: r = 0.73, cycle GXT VO_2peak and workload: r = 0.77) suggesting the performance measures may be clinically useful as proxy measures of CRF. Common comorbidities, such as lower-limb joint pain and poor balance, and participant’s fastest walking speed, should inform the choice of CRF test.]]> Tue 23 Aug 2022 11:15:21 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:48324 Tue 14 Mar 2023 16:40:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36655 Thu 28 Oct 2021 13:04:35 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37847 Thu 28 Oct 2021 12:36:07 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52627 Thu 15 Feb 2024 14:07:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:9509 Sat 24 Mar 2018 08:35:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18267 Sat 24 Mar 2018 08:04:23 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17247 Sat 24 Mar 2018 08:01:21 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20723 Sat 24 Mar 2018 08:00:20 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21817 Sat 24 Mar 2018 07:58:44 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21853 Sat 24 Mar 2018 07:55:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28647 P<0.0001, r=−0.7, r²=0.53; SIS recovery n=2970, P<0.0001, r=−0.71, r²=0.52). Proxy responses had a stronger association with BI (EQ-5D weighted score n=837, P<0.0001, r=0.78, r²=0.63; SIS recovery n=867, P<0.0001, r=0.68, r²=0.48). mRS explained more of the variation in QoL (EQ-5D weighted score=53%, recovery by SIS v3.0=52%) than NIHSS or BI and resulted in fewer mismatches between good primary outcome and poor QoL (P<0.0001, EQ-5D weighted score=8.5%; SIS recovery=10%; SIS-16=4.4%). Conclusions: The mRS seemed to align closely with stroke survivors’ interests, capturing more information on QoL than either NIHSS or BI. This further supports its recommendation as a primary outcome measure in acute stroke randomized controlled trials.]]> Sat 24 Mar 2018 07:37:14 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22149 Sat 24 Mar 2018 07:16:52 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:25468 Mon 23 Sep 2019 11:15:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51413 Mon 04 Sep 2023 14:50:35 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42735 Fri 30 Jun 2023 12:50:12 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:30579 max) immediately prior to the 1 hour of task-specific training with the therapist. Recruitment, adherence, retention, participant acceptability, and adverse events will be recorded. Clinical outcome measures will be performed pre-randomisation at baseline, at completion of the training program, and at 1 and 6 months follow-up. Primary clinical outcome measures will be the Action Research Arm Test (ARAT) and the Wolf Motor Function Test (WMFT). If aerobic exercise prior to task-specific training is acceptable, and a future phase 3 randomised controlled trial seems feasible, it should be pursued to determine the efficacy of this combined intervention for people after stroke.]]> Fri 24 Aug 2018 09:07:00 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51591 Fri 22 Sep 2023 13:48:17 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:46151 n = 18, mean age: 62.2 ± 9.9 years) performed three repeat trials of sustained maximal grasp over 8 seconds. Both hands were tested in within-day and between-day sessions, with vision and without vision. Measures of maximal tactile pressures and forces were measured for the complete grasp duration (8s) and for the plateau phase (5s). Measures of maximal tactile pressures and forces were reported using the highest value among three repeat trials, the mean of two repeat trials, and the mean of three repeat trials. Reliability was determined using changes in mean, coefficients of variation and intraclass correlation coefficients (ICCs). Pearson correlation coefficients were used to evaluate concurrent validity. Results: Changes in mean were very good, coefficients of variation were good to acceptable and ICCs were very good to good for maximal tactile pressures using the highest value among three repeat trials and the mean of three repeat trials for the complete grasp duration (8s) and for the plateau phase (5s) in the dominant hand with and without vision and in the non-dominant hand without vision for within-day and between-day sessions. Maximal tactile pressures had moderate to large correlations with grip strength. Conclusion: The TactArray device demonstrates satisfactory reliability for maximal tactile pressures during a sustained grasp for within-day and between-day testing sessions in both hands. Validity was satisfactory with grip strength in both hands.]]> Fri 11 Nov 2022 18:58:47 AEDT ]]>